8:28AM Seattle Genetics Correction: 50% of patients achieved an objective response, including 38% complete remissions; an additional 42% of patients had stable disease (SGEN) 16.13 : Yesterday we reported that patients in the co's pivotal Hodgkin lymphoma trial had all relapsed following autologous transplant, but none had received an allogeneic transplant, that comment has been removed... Yesterday, SGEN announced that data from a case series of Hodgkin lymphoma patients receiving brentuximab vedotin (SGN-35) following allogeneic stem cell transplant were presented in an oral session at the European Group for Blood and Marrow Transplantation (EBMT) Annual Meeting in Paris, France. 50% of patients achieved an objective response (12 of 24 evaluable), including 38% complete remissions; an additional 42% of patients had stable disease.
surf's up......crikey
Market Data 
Markets 
AI
